PDF(Pubmed)
Abstract：
UNASSIGNED: This study was aimed to summarize the complications and their management associated with XEN gel stent implantation.
UNASSIGNED: A systematic review of literature was conducted using Medline (via PubMed), EMBASE, the Cochrane Library databases, and China National Knowledge Infrastructure, from their inception to February 1, 2024.
UNASSIGNED: A total of 48 studies published between 2017 and 2024 were identified and included in the systematic review, including 16 original studies (retrospective or prospective clinical studies), 28 case reports, and 4 case series, which followed patients for up to 5 years. Early postoperative complications of XEN gel stent implantation include hypotony maculopathy (1.9-4.6%), occlusion (3.9-8.8%), suprachoroidal hemorrhage (SCH), choroidal detachment (0-15%), conjunctival erosion, and exposure of the XEN gel stent (1.1-2.3%), wound and bleb leaks (2.1%) and malignant glaucoma (MG) (2.2%). Mid-postoperative complications of XEN gel stent implantation included migration of XEN (1.5%), ptosis (1.2%), endophthalmitis (0.4-3%), macular edema (1.5-4.3%), hypertrophic bleb (8.8%) and subconjunctival XEN gel stent fragmentation (reported in 2 cases). Late postoperative complications reported in cases included spontaneous dislocation and intraocular degradation.
UNASSIGNED: XEN gel stent implantation is a minimally invasive glaucoma surgery (MIGS) procedure for glaucoma, known for its potential to minimize tissue damage and reduce surgical duration. However, it is crucial to note that despite these advantages, there remains a risk of severe complications, including endophthalmitis, SCH, and MG. Therefore, postoperative follow-up and early recognition of severe complications are essential for surgical management.
UNASSIGNED: A systematic review of literature was conducted using Medline (via PubMed), EMBASE, the Cochrane Library databases, and China National Knowledge Infrastructure, from their inception to February 1, 2024.
UNASSIGNED: A total of 48 studies published between 2017 and 2024 were identified and included in the systematic review, including 16 original studies (retrospective or prospective clinical studies), 28 case reports, and 4 case series, which followed patients for up to 5 years. Early postoperative complications of XEN gel stent implantation include hypotony maculopathy (1.9-4.6%), occlusion (3.9-8.8%), suprachoroidal hemorrhage (SCH), choroidal detachment (0-15%), conjunctival erosion, and exposure of the XEN gel stent (1.1-2.3%), wound and bleb leaks (2.1%) and malignant glaucoma (MG) (2.2%). Mid-postoperative complications of XEN gel stent implantation included migration of XEN (1.5%), ptosis (1.2%), endophthalmitis (0.4-3%), macular edema (1.5-4.3%), hypertrophic bleb (8.8%) and subconjunctival XEN gel stent fragmentation (reported in 2 cases). Late postoperative complications reported in cases included spontaneous dislocation and intraocular degradation.
UNASSIGNED: XEN gel stent implantation is a minimally invasive glaucoma surgery (MIGS) procedure for glaucoma, known for its potential to minimize tissue damage and reduce surgical duration. However, it is crucial to note that despite these advantages, there remains a risk of severe complications, including endophthalmitis, SCH, and MG. Therefore, postoperative follow-up and early recognition of severe complications are essential for surgical management.
摘要：
■本研究旨在总结与XEN凝胶支架植入相关的并发症及其处理方法。
■使用Medline（通过PubMed）对文献进行了系统回顾，EMBASE,Cochrane图书馆的数据库,和中国国家知识基础设施，从成立到2024年2月1日。
■确定了2017年至2024年之间发表的总共48项研究，并将其纳入系统评价中。包括16项原始研究（回顾性或前瞻性临床研究），28例病例报告，和4个案例系列，随访患者长达5年。XEN凝胶支架植入术后早期并发症包括低眼压性黄斑病变（1.9-4.6%），闭塞（3.9-8.8％），脉络膜上腔出血(SCH),脉络膜脱离(0-15%),结膜糜烂,和XEN凝胶支架的暴露（1.1-2.3％），伤口和气泡渗漏（2.1％）和恶性青光眼（MG）（2.2％）。XEN凝胶支架置入术后中期并发症包括XEN移位(1.5%)，上睑下垂（1.2%），眼内炎（0.4-3%），黄斑水肿（1.5-4.3%），肥厚性泡（8.8％）和结膜下XEN凝胶支架破裂（报告2例）。病例报告的晚期术后并发症包括自发性脱位和眼内退化。
■XEN凝胶支架植入术是一种针对青光眼的微创青光眼手术（MIGS）程序，以其最小化组织损伤和减少手术时间的潜力而闻名。然而,重要的是要注意，尽管有这些优势，仍然存在严重并发症的风险，包括眼内炎,SCH,MG。因此,术后随访和早期发现严重并发症对外科治疗至关重要.
■使用Medline（通过PubMed）对文献进行了系统回顾，EMBASE,Cochrane图书馆的数据库,和中国国家知识基础设施，从成立到2024年2月1日。
■确定了2017年至2024年之间发表的总共48项研究，并将其纳入系统评价中。包括16项原始研究（回顾性或前瞻性临床研究），28例病例报告，和4个案例系列，随访患者长达5年。XEN凝胶支架植入术后早期并发症包括低眼压性黄斑病变（1.9-4.6%），闭塞（3.9-8.8％），脉络膜上腔出血(SCH),脉络膜脱离(0-15%),结膜糜烂,和XEN凝胶支架的暴露（1.1-2.3％），伤口和气泡渗漏（2.1％）和恶性青光眼（MG）（2.2％）。XEN凝胶支架置入术后中期并发症包括XEN移位(1.5%)，上睑下垂（1.2%），眼内炎（0.4-3%），黄斑水肿（1.5-4.3%），肥厚性泡（8.8％）和结膜下XEN凝胶支架破裂（报告2例）。病例报告的晚期术后并发症包括自发性脱位和眼内退化。
■XEN凝胶支架植入术是一种针对青光眼的微创青光眼手术（MIGS）程序，以其最小化组织损伤和减少手术时间的潜力而闻名。然而,重要的是要注意，尽管有这些优势，仍然存在严重并发症的风险，包括眼内炎,SCH,MG。因此,术后随访和早期发现严重并发症对外科治疗至关重要.
